Mar 2, 2023
Marijuana stocks don’t seem to be making the big headlines they used to. But that doesn’t mean the green wave has stopped.
Don't miss
- 'Hold onto your money': Jeff Bezos issued a financial warning, says you might want to rethink buying a 'new automobile, refrigerator, or whatever' — here are 3 better recession-proof buys
- UBS says 61% of millionaire collectors allocate up to 30% of their overall portfolio to this exclusive asset class
- Rich young Americans have lost confidence in the stock market — and are betting on these 3 assets instead. Get in now for strong long-term tailwinds
In fact, it's easier than ever to — legally — access marijuana. As of 2022, 21 states and the District of Columbia offer legal recreational cannabis to their residents. That means, according to Pew Research Center, that 43% of U.S. adults now live in an area that has legalized marijuana use.
But maybe it’s not your thing. Still, there could be some green in it for you. If you don’t care to take a toke, why not let cannabis puff up your portfolio instead?
Advertisement
Here’s a look at three marijuana stocks ready to capitalize on the growing trend towards legalization. They’re listed on stock exchanges in Canada but trade over the counter in the U.S. — and analysts also see major upside in this trio.
Must Read
- Dave Ramsey warns nearly 50% of Americans are making 1 big Social Security mistake — here’s what it is and the simple steps to fix it ASAP
- Robert Kiyosaki begs investors not to miss this ‘explosion’ — says this 1 asset will surge 400% in a year
- Vanguard reveals what could be coming for U.S. stocks, and it’s raising alarm bells for retirees. Here’s why and how to protect yourself
Join 250,000+ readers and get Moneywise’s best stories and exclusive interviews first — clear insights curated and delivered weekly. Subscribe now.
Trulieve Cannabis Corp (TCNNF)
Trulieve Cannabis entered the cannabis industry by winning the first medical marijuana application in Florida in 2015. Today, it has 100 stores in the Sunshine State, and around 180 operated and affiliated dispensaries nationwide.
The company claims that it has leading market positions not just in Florida, but also in Arizona and Pennsylvania.
Trulieve’s financials have grown tremendously, and even the COVID-19 pandemic couldn’t stop the momentum. In 2020, revenue rose 106% from the 2019 level to $521.5 million.
In 2021, revenue surged another 80% to $938.4 million.
According to the latest earnings report, Trulieve earned $300.8 million of revenue in Q3 of 2022, up 34% year over year.
The stock, however, has plunged nearly 70% over the last 12 months.
Advertisement
Canaccord analyst Derek Dley sees a rebound on the horizon. The analyst has a ‘buy’ rating on Trulieve and a price target of C$50 on its Canada-listed shares — implying a potential upside of 488%.
Green Thumb Industries (GTBIF)
Green Thumb is a vertically integrated cannabis company headquartered in Chicago. It has 18 cultivation and manufacturing facilities, six consumer product brands, 77 open retail locations, and operations in 15 U.S. markets.
Just like Trulieve, Green Thumb stock hasn’t been a hot commodity: shares are down more than 50% in the last year.
Business, however, is still on the rise.
Read more: Here's how much the average American 60-year-old holds in retirement savings — how does your nest egg compare?
Advertisement
In 2022, the company generated $1.0 billion of revenue, representing a 13.9% increase year over year.
Stifel analyst Andrew Partheniou has a ‘buy’ rating on Green Thumb and a price target of C$30 on its Canada-listed shares. Since these shares trade at C$11.20 right now, the price target represents a potential upside of 168%.
Read More: Dave Ramsey says this 7-step plan ‘works every single time’ to kill debt, get rich in America — and that ‘anyone’ can do it
Curaleaf Holdings (CURLF)
With a market cap of around $3.1 billion CAD, Curaleaf is a bigger company than both Trulieve and Green Thumb.
It has a huge presence in the U.S. cannabis industry, with 29 cultivation sites, approximately 4.4 million square feet of cultivation capacity, 148 retail locations and around 2,200 wholesale partner accounts.
In Q3 of 2022, revenue grew 7% year over year to $340 million.
Still, this pot heavyweight is not immune to the industry-wide sell-off as shares are down about 42% over the last six months.
Alliance Global Partners analyst Aaron Grey has a ‘buy’ rating on Curaleaf and a price target of C$12 on its Canada-listed shares — roughly 136% above where they sit today.
What to read next
- You could be the landlord of Walmart, Whole Foods and CVS (and collect fat grocery store-anchored income on a quarterly basis)
- The US dollar has lost 98% of its purchasing power since 1971 — invest in this stable asset before you lose your retirement fund
- Americans are paying nearly 40% more on home insurance compared to 12 years ago — here's how to spend less on peace of mind
You May Also Like
- Turning 50 with $0 saved for retirement? Most people don’t realize they’re actually just entering their prime earning decade. Here are 6 ways to catch up fast
- This 20-year-old lotto winner refused $1M in cash and chose $1,000/week for life. Now she’s getting slammed for it. Which option would you pick?
- Warren Buffett used these 8 repeatable money rules to turn $9,800 into a $150B fortune. Start using them today to get rich (and stay rich)
- Here are 5 easy ways to own multiple properties like Bezos and Beyoncé. You can start with $10 (and no, you don’t have to manage a single thing)
Jing is an investment reporter for MoneyWise. He is an avid advocate of investing for passive income. Despite the ups and downs he’s been through with the markets, Jing believes that you can generate a steadily increasing income stream by investing in high quality companies.
